Literature DB >> 22081075

Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression.

D Mérino1, A Strasser, P Bouillet.   

Abstract

Overexpression of the transcriptional regulator Myc is thought to be the cause or a contributing factor in the development of a large number of human lymphomas and certain other cancers. Apoptotic cell death constitutes a tumor suppressive mechanism, particularly in the context of Myc overexpression. Accordingly, lymphoma development in Eμ-Myc transgenic mice, which mimic the Myc/IgH chromosomal translocation that causes Burkitt lymphoma, is accelerated by concomitant overexpression of anti-apoptotic Bcl-2 family members or loss of pro-apoptotic BH3-only proteins, such as Bim. Bim binds with high affinity to all pro-survival Bcl-2-like proteins and can also interact with Bax/Bak, but it remains unclear which of these interactions are critical for its tumor suppressive function. We have previously generated knock-in mutant mice in which the BH3 region of Bim has been exchanged with that for Bad, Noxa or Puma so that it can only bind to select pro-survival Bcl-2-like proteins: Bim(Bad) binding to Bcl-2, Bcl-x(L) and Bcl-w, but not Mcl-1 or A1; Bim(Noxa) binding only to Mcl-1 and A1 and as a control, Bim(Puma), which can still bind all pro-survival Bcl-2-like proteins. We have now inter-crossed these Bim mutant mice with Eμ-Myc transgenic mice, and found that both the Bim(Bad) and the Bim(Noxa) mutations but not the Bim(Puma) mutation greatly accelerate Myc-induced lymphoma development and increase leukemic burden. These results demonstrate that for optimal tumor suppressive activity, Bim must be able to interact with all and not just select pro-survival Bcl-2 family members.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22081075      PMCID: PMC3361534          DOI: 10.1038/onc.2011.508

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.

Authors:  Tomomi Kuwana; Lisa Bouchier-Hayes; Jerry E Chipuk; Christine Bonzon; Barbara A Sullivan; Douglas R Green; Donald D Newmeyer
Journal:  Mol Cell       Date:  2005-02-18       Impact factor: 17.970

Review 2.  The BCL-2 protein family: opposing activities that mediate cell death.

Authors:  Richard J Youle; Andreas Strasser
Journal:  Nat Rev Mol Cell Biol       Date:  2008-01       Impact factor: 94.444

Review 3.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

Authors:  Jerry E Chipuk; Douglas R Green
Journal:  Trends Cell Biol       Date:  2008-03-07       Impact factor: 20.808

4.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.

Authors:  A Strasser; A W Harris; M L Bath; S Cory
Journal:  Nature       Date:  1990-11-22       Impact factor: 49.962

5.  Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival.

Authors:  A Strasser; A G Elefanty; A W Harris; S Cory
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

6.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM.

Authors:  Hiroyuki Tagawa; Sivasundaram Karnan; Ritsuro Suzuki; Keitaro Matsuo; Xiaohua Zhang; Akinobu Ota; Yasuo Morishima; Shigeo Nakamura; Masao Seto
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

7.  Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.

Authors:  Priscilla N Kelly; Hamsa Puthalakath; Jerry M Adams; Andreas Strasser
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

8.  Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis.

Authors:  E M Michalak; E S Jansen; L Happo; M S Cragg; L Tai; G K Smyth; A Strasser; J M Adams; C L Scott
Journal:  Cell Death Differ       Date:  2009-01-16       Impact factor: 15.828

9.  Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.

Authors:  Sean P Garrison; John R Jeffers; Chunying Yang; Jonas A Nilsson; Mark A Hall; Jerold E Rehg; Wen Yue; Jian Yu; Lin Zhang; Mihaela Onciu; Jeffery T Sample; John L Cleveland; Gerard P Zambetti
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

10.  Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma.

Authors:  E Anderton; J Yee; P Smith; T Crook; R E White; M J Allday
Journal:  Oncogene       Date:  2007-07-23       Impact factor: 9.867

View more
  7 in total

1.  Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.

Authors:  Thibault Dupont; Shao Ning Yang; Jayeshkumar Patel; Katerina Hatzi; Alka Malik; Wayne Tam; Peter Martin; John Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Oncotarget       Date:  2016-01-19

2.  Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency.

Authors:  Guo Wei; Adam A Margolin; Leila Haery; Emily Brown; Lisa Cucolo; Bina Julian; Shyemaa Shehata; Andrew L Kung; Rameen Beroukhim; Todd R Golub
Journal:  Cancer Cell       Date:  2012-04-17       Impact factor: 31.743

3.  Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Ernesto Diaz-Flores; Evan Q Comeaux; Kailyn L Kim; Ella Melnik; Kyle Beckman; Kara L Davis; Kevin Wu; Jon Akutagawa; Olga Bridges; Roberta Marino; Margo Wohlfeil; Benjamin S Braun; Charles G Mullighan; Mignon L Loh
Journal:  Cancer Res       Date:  2019-03-12       Impact factor: 12.701

Review 4.  Programming cancer cells for high expression levels of Mcl1.

Authors:  Franziska Ertel; Mai Nguyen; Anne Roulston; Gordon C Shore
Journal:  EMBO Rep       Date:  2013-03-12       Impact factor: 8.807

Review 5.  MicroRNA and signal transduction pathways in tumor radiation response.

Authors:  Luqing Zhao; Xiongbin Lu; Ya Cao
Journal:  Cell Signal       Date:  2013-04-17       Impact factor: 4.315

Review 6.  Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.

Authors:  Luqing Zhao; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

7.  Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.

Authors:  L Happo; B Phipson; G K Smyth; A Strasser; C L Scott
Journal:  Cell Death Dis       Date:  2012-05-10       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.